Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00038909
Status:
COMPLETED
Last Update Posted:
2013-02-08
First Post:
2002-06-05
Brief Title:
Study Evaluating ReFacto in Hemophilia A
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
Factor VIII Mutation Testing Program in Previously Untreated Patients PUPs With Hemophilia A Participating in ReFacto Study
Status:
COMPLETED
Status Verified Date:
2013-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To identify the causative mutations in previously untreated patients with hemophilia A enrolled in the ReFacto clinical safety and efficacy study CTN 93-R833-0XXC9741-28 using two established hemophilia mutation testing laboratories one in Europe and one in North America
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None